ARID1A突变对结直肠癌分子特征的影响
该研究整合7978例结直肠癌数据,分析ARID1A突变与分子特征、临床病理及通路的关系。发现ARID1A突变样本多见MSI-H、TMB-H、PD-L1表达及CTL浸润,且与右半原发、早期及DNA修复通路调控相关,为基于突变状态的个体化治疗提供线索。
要点
- ARID1A突变与MSI-H、TMB-H及T细胞炎症微环境相关
- 无MSI-H的ARID1A突变样本仍表现为TMB-H和PD-L1高表达
- ARID1A突变常见于右半结肠和早期肿瘤且涉及耐药通路
核心结论
- ARID1A突变可能为结直肠癌个体化治疗提供新思路。
研究设计与样本
- 整合7978例结直肠癌数据,包括一个CLIA认证实验室数据集和三个独立公开数据集。
- 采用二代测序、RNA测序和免疫组化分析ARID1A突变与分子特征、临床病理及通路的关系。
主要发现
- 在发现和验证队列中,ARID1A突变样本比野生型更常见MSI-H、TMB-H、PD-L1表达及高估计浸润CTL。
- 即使无MSI-H,ARID1A突变样本仍表现为TMB-H、PD-L1高表达和高估计浸润CTL。
- ARID1A突变更多见于右半原发和早期肿瘤。
- ARID1A突变肿瘤共现染色质修饰、DNA修复、WNT信号及EGFR抑制剂耐药通路相关基因突变。
- ARID1A突变样本中化疗/放疗敏感性关键基因受抑制。
临床怎么用
- 可考虑将ARID1A突变状态纳入结直肠癌分子分型以辅助免疫治疗决策。
- 对ARID1A突变且无MSI-H者仍需关注TMB和PD-L1评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ARID1A is a key subunit of the SWItch/Sucrose Non-Fermentable (SWI/SNF) complex which regulates dynamic repositioning of nucleosomes to repair DNA damage. Only small pilot studies have evaluated the role of ARID1A mutation in colorectal cancer (CRC). The aim of the present study was to explore the potential impact of ARID1A mutation on clinicopathological and molecular characteristics in CRC. METHODS: We used integrated data sets of 7978 CRC cases (one data set from a clinical laboratory improvement amendments [CLIA]-certified laboratory and three independent published data sets). The associations of ARID1A mutation with molecular characteristics including immune profile (the status of microsatellite instability [MSI], tumour mutational burden [TMB], programmed death ligand 1 [PD-L1] and estimated infiltrating immune cells), clinicopathological features and related pathways were analysed using next-generation sequencing, RNA sequencing and immunohistochemistry. RESULTS: ARID1A mutant samples had more genomically unstable tumour features (MSI-high and TMB-high) and exhibited more characteristics of a T-cell-inflamed microenvironment (PD-L1 expression and high estimated infiltrating cytotoxic T lymphocytes [CTLs]) than ARID1A wild-type samples in the discovery and validation cohorts. Even ARID1A mutant samples without MSI-high status were TMB-high, had high levels of PD-L1 expression and high estimated infiltrating CTLs. ARID1A mutations were more common with right-sided primary and earlier stage tumours. ARID1A mutant tumours mainly had co-occurring gene mutations related to chromatin modifying, DNA repair, WNT signalling and epidermal growth factor receptor inhibitor resistance pathways, and ARID1A mutations strongly regulated DNA repair pathways. Key genes for chemotherapy/radiotherapy sensitivity were suppressed in ARID1A mutant samples. CONCLUSIONS: Our findings may provide novel insights to develop individualised approaches for treatment of CRC based on ARID1A mutation status.
引用
- Tokunaga R, Xiu J, Goldberg RM, et al. The impact of ARID1A mutation on molecular characteristics in colorectal cancer. Eur J Cancer. 2020. PMID: 33080474. doi:10.1016/j.ejca.2020.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。